{"id":"NCT00441116","sponsor":"GlaxoSmithKline","briefTitle":"A Study To Assess The Efficacy And Safety Of Dutasteride 0.5mg Once Daily For 6 Months In The Treatment Of Male Subjects With Androgenetic Alopecia","officialTitle":"An Randomised, Double-blind, Placebo-controlled, Parallel Group Study to Assess the Efficacy and Safety of Dutasteride 0.5mg Once Daily for 6 Months in the Treatment of Male Subjects With Androgenetic Alopecia (Norwood-Hamilton Classification Type IIIv, IV and V)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2006-12-15","primaryCompletion":"2008-01-21","completion":"2008-01-21","firstPosted":"2007-02-28","resultsPosted":"2009-04-22","lastUpdate":"2018-08-16"},"enrollment":153,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Alopecia"],"interventions":[{"type":"DRUG","name":"Dutasteride 0.5mg oral tablets","otherNames":[]}],"arms":[{"label":"Dutasteride","type":"PLACEBO_COMPARATOR"}],"summary":"The aim of this Phase III study is to compare the efficacy, safety and tolerability of dutasteride (0.5mg) with placebo for 6 months, in Korean male subjects with androgenetic alopecia in the vertex region, types IIIv, IV and V according to the modified Norwood-Hamilton Classification.","primaryOutcome":{"measure":"Change From Baseline Hair Growth Assessed by Macrophotographic Technique (Hair Count) in the Vertex at 6 Months.","timeFrame":"Baseline and 6 months","effectByArm":[{"arm":"Dutasteride","deltaMin":148.14,"sd":36.27},{"arm":"Placebo","deltaMin":144.27,"sd":32.33}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0319"}]},"eligibility":{"minAge":"18 Years","sex":"MALE","healthyVolunteers":false,"inclusionCount":1,"exclusionCount":1},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":[],"seeAlso":["https://clinicalstudydatarequest.com"]},"adverseEventsSummary":{"seriousAny":{"events":0},"commonTop":["Nasopharyngitis"]}}